Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.
- Conditions
- Interventions
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 22
- Registration Number
- NCT02977156
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇫🇷Hopital Saint Louis, Paris, France
🇫🇷Centre Hospitalier Lyon Sud, Pierre-Bénite, France
A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-11-10
- Last Posted Date
- 2021-04-26
- Target Recruit Count
- 200
- Registration Number
- NCT02960906
- Locations
- 🇫🇷
Centre Francois Baclesse, Caen, France
🇫🇷Hôpital Cochin, Paris, France
🇫🇷Centre Antoine Lacassagne, Nice, France
NeoVax Plus Ipilimumab in Renal Cell Carcinoma
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Patrick Ott, MD, PhD
- Target Recruit Count
- 19
- Registration Number
- NCT02950766
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study to Nivolumab Following Preoperative Chemoradiotherapy
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Takayuki Yoshino
- Target Recruit Count
- 90
- Registration Number
- NCT02948348
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵Hokkaido University, Sapporo, Hokkaido, Japan
🇯🇵Osaka National Hospital, Osaka, Japan
A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases
- Conditions
- Interventions
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Target Recruit Count
- 56
- Registration Number
- NCT02941744
- Locations
- 🇧🇪
UZ Brussel, Jette, Brabant, Belgium
Ipilimumab and Nivolumab in Leptomeningeal Metastases
- First Posted Date
- 2016-10-20
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT02939300
- Locations
- 🇺🇸
Massachusetts general Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab
- Conditions
- Interventions
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1
- Registration Number
- NCT02935790
- Locations
- 🇺🇸
NYU Langone Medical Center, New York, New York, United States
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
- Conditions
- Interventions
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Olivia Newton-John Cancer Research Institute
- Target Recruit Count
- 120
- Registration Number
- NCT02923934
- Locations
- 🇦🇺
Blacktown Hospital, Sydney, New South Wales, Australia
🇦🇺Border Medical Oncology Unit, Albury, New South Wales, Australia
🇦🇺Monash Health, Clayton, Victoria, Australia
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Inspirna, Inc.
- Target Recruit Count
- 146
- Registration Number
- NCT02922764
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Sarah Cannon Research Institute, Denver, Colorado, United States
Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity
- Conditions
- Interventions
- First Posted Date
- 2016-09-29
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT02919683
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.